AstraZeneca lung and breast cancer data at WCLC and ESMO.
The Pharma Data
SEPTEMBER 2, 2021
Changing treatment paradigms with industry-leading PARP inhibitors and next-wave DNA damage response therapies. Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN. DNA damage response. Lead author. Abstract title. Presentation details. Immuno-Oncology.
52 
Let's personalize your content